Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review

Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel GellerClinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USAObjective: This review examines and summarizes the pharmacodynamic and p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9b48f4ec2c6b4dfda160713077c56263
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b48f4ec2c6b4dfda160713077c56263
record_format	dspace
spelling	oai:doaj.org-article:9b48f4ec2c6b4dfda160713077c562632021-12-02T06:15:59ZAtomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review1176-63281178-2021https://doaj.org/article/9b48f4ec2c6b4dfda160713077c562632009-03-01T00:00:00Zhttp://www.dovepress.com/atomoxetine-for-the-treatment-of-attention-deficithyperactivity-disord-a2988https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel GellerClinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USAObjective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine&rsquo;s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine&rsquo;s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.Keywords: ADHD, atomoxetine, pediatric Paul HammernessKatherine McCarthyElizabeth MancusoCassandra GendronDaniel GellerDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 215-226 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Paul Hammerness Katherine McCarthy Elizabeth Mancuso Cassandra Gendron Daniel Geller Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
description	Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel GellerClinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USAObjective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine&rsquo;s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine&rsquo;s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.Keywords: ADHD, atomoxetine, pediatric
format	article
author	Paul Hammerness Katherine McCarthy Elizabeth Mancuso Cassandra Gendron Daniel Geller
author_facet	Paul Hammerness Katherine McCarthy Elizabeth Mancuso Cassandra Gendron Daniel Geller
author_sort	Paul Hammerness
title	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_short	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_full	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_fullStr	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_full_unstemmed	Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_sort	atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/9b48f4ec2c6b4dfda160713077c56263
work_keys_str_mv	AT paulhammerness atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview AT katherinemccarthy atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview AT elizabethmancuso atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview AT cassandragendron atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview AT danielgeller atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview
_version_	1718400004290248704

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review

Ejemplares similares